Status:
COMPLETED
New Drugs in the Treatment of Mood Disorders
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
Anxiety Disorder
Mood Disorder
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
This clinical study compares the effectiveness of two anticonvulsants Lamotrigine (Lamictal) Monotherapy and Gabapentin (Neurontin) in patients with treatment resistant affective disorders. We initial...
Detailed Description
The anticonvulsants carbamazepine (CBZ) and valproate (VPA) have efficacy in the treatment of mood disorders, suggesting that other anticonvulsants with related mechanisms of action may have similar u...
Eligibility Criteria
Patients between the ages of 18 and 75 who satisfy DSM-III-R criteria for mood disorders, are refractory to at least two conventional treatments, and are inpatients or outpatients at the NIMH are invited to participate provided that the following criteria are fulfilled:
Subjects having serious medical illness (or meeting current psychoactive substance dependence will be excluded from entry.)
Key Trial Info
Start Date :
May 1 1995
Trial Type :
INTERVENTIONAL
End Date :
May 1 2001
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00001482
Start Date
May 1 1995
End Date
May 1 2001
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Mental Health (NIMH)
Bethesda, Maryland, United States, 20892